Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
出版年份 2022 全文链接
标题
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
作者
关键词
-
出版物
LANCET
Volume 399, Issue 10342, Pages 2200-2211
出版商
Elsevier BV
发表日期
2022-06-10
DOI
10.1016/s0140-6736(22)00688-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Higher vs Standard Adalimumab Induction Dosing Regimens and 2 Maintenance Strategies: Randomized SERENE CD Trial Results
- (2022) Geert R. D‘Haens et al. GASTROENTEROLOGY
- Su451 TREATMENT PATTERNS IN BIOLOGIC-EXPERIENCED CROHN'S DISEASE PATIENTS USING THREE LARGE COMMERCIAL CLAIMS DATABASES IN THE UNITED STATES
- (2021) Amanda M. Teeple et al. GASTROENTEROLOGY
- Superior treatment persistence with ustekinumab in Crohn’s disease and vedolizumab in ulcerative colitis compared with anti‐TNF biological agents: real‐world registry data from the Persistence Australian National IBD Cohort (PANIC) study
- (2021) Yanna Ko et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease
- (2021) Joseph D. Feuerstein et al. GASTROENTEROLOGY
- Real-World Persistence, Maintenance Dosing, and Pre-Post Corticosteroid and Opioid Use Among Crohn’s Disease Patients with Prescription Claims for Ustekinumab in the USA
- (2021) Zhijie Ding et al. Drugs - Real World Outcomes
- Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn’s Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States
- (2020) Camilo Obando et al. ADVANCES IN THERAPY
- Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications
- (2020) Laura E Targownik et al. Journal of Crohns & Colitis
- Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease
- (2018) S. Singh et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- ACG Clinical Guideline: Management of Crohn’s Disease in Adults
- (2018) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease
- (2018) Omoniyi J. Adedokun et al. GASTROENTEROLOGY
- Upfront Combination Therapy, Compared with Monotherapy, for Patients Not Previously Treated with a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study
- (2018) Laura E. Targownik et al. Clinical Gastroenterology and Hepatology
- Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease
- (2016) J. Cosnes et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Adalimumab Monotherapy and a Combination with Azathioprine for Crohn’s Disease: A Prospective, Randomized Trial
- (2016) Takayuki Matsumoto et al. Journal of Crohns & Colitis
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
- (2016) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: A systematic review and meta-analysis
- (2014) Uri Kopylov et al. Journal of Crohns & Colitis
- Advanced multiplicity adjustment methods in clinical trials
- (2013) Mohamed Alosh et al. STATISTICS IN MEDICINE
- Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3years for adalimumab-treated patients with early Crohn's disease
- (2012) S. Schreiber et al. Journal of Crohns & Colitis
- Crohn's disease
- (2012) Daniel C Baumgart et al. LANCET
- Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of Two Adalimumab Treatment Schedule Strategies for Moderate-to-Severe Crohn's Disease: Results From the CHARM Trial
- (2009) Jean-Frédéric Colombel et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now